Jeffrey M Rosen

19PUBLICATIONS
77CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunityTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Aug 17, 2026
MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable antitumor immunity in triple negative breast cancer.

|Jan 03, 2026
Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.

Diego A Pedroza, Xueying Yuan, Fengshuo Liu

|Jun 26, 2025
Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers.

Diego A Pedroza, Xueying Yuan, Fengshuo Liu

|May 07, 2024
CBP/P300 BRD Inhibition Reduces Neutrophil Accumulation and Activates Antitumor Immunity in TNBC.

Xueying Yuan, Xiaoxin Hao, Hilda L Chan

|Aug 21, 2023
Targeted Inhibition of lncRNA Malat1 Alters the Tumor Immune Microenvironment in Preclinical Syngeneic Mouse Models of Triple-Negative Breast Cancer.

Oluwatoyosi Adewunmi, Yichao Shen, Xiang H-F Zhang

|Dec 09, 2022
LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells.

Ho Ngai, Gabriel A Barragan, Gengwen Tian

Pageof 4

Frequent Collaborators

11 joint publications

Xiang H-F Zhang

5 joint publications

Diego A Pedroza

5 joint publications

Na Zhao

4 joint publications

Charles M Perou